Presentation of NEX-22 phase I data: A once-monthly GLP-1 injection receives positive response at the 85th ADA Scientific Sessions in Chicago
24 juni, 08:00
Nanexa announces that the poster titled "A Single Ascending Dose Study of a Once-monthly Liraglutide Formulation in Participants with Type 2 Diabetes" was presented by the renowned diabetes researcher Dr. Hans de Vries, on Sunday, June 22, at the American Diabetes Association’s 85th Scientific Sessions. The poster, which presented all data, including the 30 mg NEX-22 dose cohort, was very well received, and there has been significant interest in the first published clinical data with a once-montly long-acting injection of a GLP-1 drug. A 30 mg dose of NEX-22 shows exposure for up to 36 days without significant gastrointestinal side effects. This is not only highly positive for NEX-22, but all other potential GLP-1/GIP formulations which make use of PharmaShell.
The ADA’s Scientific Sessions is the world’s largest diabetes meeting, convening more than 11,000 attendees from around the globe to share cutting-edge scientific discoveries and advancements in diabetes care and innovation.
"We are very pleased with the attention we have received and the new contacts we have made during this important event. We see a great need for drugs that improve and simplify the treatment of both Type 2 diabetes and obesity," says David Westberg, CEO of Nanexa. "We are happy to being part of the development of important pharmaceuticals that can enhance the quality of life for many people."
The poster is already digitally available to all ADA members and conference attendees, and in August, it will also be publicly available on ADA’s official portal. The poster is also available on Nanexa’s website.
Authors of the poster: Dr. Hans de Vries, Dr. Tim Heise, Dr. Grit Andersen, Kristine Bäck, Erik Westrin, Maria Nehlin, Marie Gårdmark and Dr. Owe Luhr.
For additional information, please contact:
David Westberg – CEO, Nanexa AB (publ)
Phone: +46 70 942 83 03
Email: david.westberg@nanexa.se
www.nanexa.com
The company’s Certified Adviser is DNB Carnegie Investment Bank AB (publ).
About Nanexa AB (publ)
Nanexa is a pharmaceutical company developing injectable drug products based on the proprietary and innovative drug delivery system PharmaShell® – the high drug load delivery system enabling the next generation long-acting injectables through atomic layer precision. Nanexa develops its own products and also has collaboration agreements with several pharma companies, among others Novo Nordisk and AstraZeneca.
Nanexa’s share is listed on Nasdaq First North Growth Market in Stockholm (NANEXA).
Attachments
Ämnen i artikeln
Presentation of NEX-22 phase I data: A once-monthly GLP-1 injection receives positive response at the 85th ADA Scientific Sessions in Chicago
24 juni, 08:00
Nanexa announces that the poster titled "A Single Ascending Dose Study of a Once-monthly Liraglutide Formulation in Participants with Type 2 Diabetes" was presented by the renowned diabetes researcher Dr. Hans de Vries, on Sunday, June 22, at the American Diabetes Association’s 85th Scientific Sessions. The poster, which presented all data, including the 30 mg NEX-22 dose cohort, was very well received, and there has been significant interest in the first published clinical data with a once-montly long-acting injection of a GLP-1 drug. A 30 mg dose of NEX-22 shows exposure for up to 36 days without significant gastrointestinal side effects. This is not only highly positive for NEX-22, but all other potential GLP-1/GIP formulations which make use of PharmaShell.
The ADA’s Scientific Sessions is the world’s largest diabetes meeting, convening more than 11,000 attendees from around the globe to share cutting-edge scientific discoveries and advancements in diabetes care and innovation.
"We are very pleased with the attention we have received and the new contacts we have made during this important event. We see a great need for drugs that improve and simplify the treatment of both Type 2 diabetes and obesity," says David Westberg, CEO of Nanexa. "We are happy to being part of the development of important pharmaceuticals that can enhance the quality of life for many people."
The poster is already digitally available to all ADA members and conference attendees, and in August, it will also be publicly available on ADA’s official portal. The poster is also available on Nanexa’s website.
Authors of the poster: Dr. Hans de Vries, Dr. Tim Heise, Dr. Grit Andersen, Kristine Bäck, Erik Westrin, Maria Nehlin, Marie Gårdmark and Dr. Owe Luhr.
For additional information, please contact:
David Westberg – CEO, Nanexa AB (publ)
Phone: +46 70 942 83 03
Email: david.westberg@nanexa.se
www.nanexa.com
The company’s Certified Adviser is DNB Carnegie Investment Bank AB (publ).
About Nanexa AB (publ)
Nanexa is a pharmaceutical company developing injectable drug products based on the proprietary and innovative drug delivery system PharmaShell® – the high drug load delivery system enabling the next generation long-acting injectables through atomic layer precision. Nanexa develops its own products and also has collaboration agreements with several pharma companies, among others Novo Nordisk and AstraZeneca.
Nanexa’s share is listed on Nasdaq First North Growth Market in Stockholm (NANEXA).
Attachments
Ämnen i artikeln
-992x558.webp&w=3840&q=75)
Aktierekommendationer
Analyser
-160x160.jpg&w=3840&q=75)
Oljepriset
-992x558.png&w=3840&q=75)
.jpg&w=3840&q=75)
Mest läst
Aktierekommendationer
Analyser
Oljepriset
Marknadsöversikt
1 DAG %
Senast
1 mån
Privatekonomi med Placeras expert
Affärsvärlden
